Yanni Susan E, Barnett Joshua M, Clark Monika L, Penn John S
Department of Cell and Developmental Biology, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, USA.
Invest Ophthalmol Vis Sci. 2009 Nov;50(11):5479-86. doi: 10.1167/iovs.09-3652. Epub 2009 Jun 3.
PGE(2) binds to PGE(2) receptors (EP(1-4)). The purpose of the present study was to investigate the role of the EP(4) receptor in angiogenic cell behaviors of retinal Müller cells and retinal microvascular endothelial cells (RMECs) and to assess the efficacy of an EP(4) antagonist in rat models of oxygen-induced retinopathy (OIR) and laser-induced choroidal neovascularization (LCNV).
Müller cells derived from COX-2-null mice were treated with increasing concentrations of the EP(4) agonist PGE(1)-OH, and wild-type Müller cells were treated with increasing concentrations of the EP(4) antagonist L-161982; VEGF production was assessed. Human RMECs (HRMECs) were treated with increasing concentrations of L-161982, and cell proliferation and tube formation were assessed. Rats subjected to OIR or LCNV were administered L-161982, and the neovascular area was measured.
COX-2-null mouse Müller cells treated with increasing concentrations of PGE(1)-OH demonstrated a significant increase in VEGF production (P < or = 0.0165). Wild-type mouse Müller cells treated with increasing concentrations of L-161982 demonstrated a significant decrease in VEGF production (P < or = 0.0291). HRMECs treated with increasing concentrations of L-161982 demonstrated a significant reduction in VEGF-induced cell proliferation (P < or = 0.0033) and tube formation (P < 0.0344). L-161982 treatment significantly reduced pathologic neovascularization in OIR (P < 0.0069) and LCNV (P < or = 0.0329).
Preliminary investigation has demonstrated that EP(4) activation or inhibition influences the behaviors of two retinal cell types known to play roles in pathologic ocular angiogenesis. These findings suggest that the EP(4) receptor may be a valuable therapeutic target in neovascular eye disease.
前列腺素E2(PGE2)与前列腺素E2受体(EP1 - 4)结合。本研究的目的是探讨EP4受体在视网膜穆勒细胞和视网膜微血管内皮细胞(RMECs)血管生成细胞行为中的作用,并评估EP4拮抗剂在氧诱导性视网膜病变(OIR)和激光诱导性脉络膜新生血管形成(LCNV)大鼠模型中的疗效。
用浓度递增的EP4激动剂PGE1 - OH处理源自COX - 2基因敲除小鼠的穆勒细胞,并用浓度递增的EP4拮抗剂L - 161982处理野生型穆勒细胞;评估血管内皮生长因子(VEGF)的产生。用浓度递增的L - 161982处理人RMECs(HRMECs),并评估细胞增殖和管腔形成。对患有OIR或LCNV的大鼠给予L - 161982,并测量新生血管面积。
用浓度递增的PGE1 - OH处理COX - 2基因敲除小鼠穆勒细胞,VEGF产生显著增加(P≤0.0165)。用浓度递增的L - 161982处理野生型小鼠穆勒细胞,VEGF产生显著减少(P≤0.0291)。用浓度递增的L - 161982处理HRMECs,VEGF诱导的细胞增殖(P≤0.0033)和管腔形成(P < 0.0344)显著降低。L - 161982治疗显著减少了OIR(P < 0.0069)和LCNV(P≤0.0329)中的病理性新生血管形成。
初步研究表明,EP4的激活或抑制会影响已知在病理性眼部血管生成中起作用的两种视网膜细胞类型的行为。这些发现表明,EP4受体可能是新生血管性眼病的一个有价值的治疗靶点。